Table 2.
Sample Demographic, Psychiatric, and HIV-Disease Characteristics (N=100)
| Variable | Mean (SD) or % | Range |
|---|---|---|
| Demographics | ||
| Age | 58.2 (6.5) | 50 – 79 |
| Sex (% Male) | 88% | – |
| Education | 14.3 (2.6) | 8 – 20 |
| Race (% White) | 82% | – |
| HIV Characteristics | ||
| Current CD4* | 597 (365.0 – 776.0) | 6 – 1,606 |
| Nadir CD4* | 135.5 (39.5 – 300.0) | 0 – 850 |
| AIDS Status (% Yes) | 66% | – |
| ART status (% On) | 98% | – |
| Plasma Viral Load (% Undetectable) | 92% | – |
| Est. Duration HIV Infection (yrs) | 18.0 (8.0) | 1 – 30 |
| Comorbidities | ||
| Hypertension (% with) | 50% | |
| Diabetes (% with) | 26% | |
| HCV (% with) | 22% | |
| Mental Health | ||
| Beck Depression Inventory Score* | 8 (3 – 16.8) | 0 – 44 |
| Lifetime MDD Diagnosis (% Yes) | 60% | – |
| Current MDD Diagnosis (% Yes) | 14% | – |
| Lifetime Substance Diagnosis (% Yes) | 70% | – |
| Current Substance Diagnosis (% Yes) | 6% | – |
| Gold Standard Neurocognitive Impairment (% Yes) | 57% | – |
| MoCA Impaired (<=26) | 67% | |
| MoCA Total Score | 25.2 (3.0) | 15 – 30 |
| Functional Measures | ||
| IADL Declines* | 1 (0 – 2) | 0 – 9 |
| Cognitive Symptoms* | 2 (0 – 9) | 0 – 31 |
| Karnofsky Score | 87.2 (10.6) | 50 – 100 |
| IADL Dependent ** | 20% |
Notes
ART=antiretroviral therapy; IADL = instrumental activities of daily living; MDD=Major Depressive Disorder.
*
Median (IQR) reported for these variables.
**
Component for the everyday functioning impairment criteria for HIV-associated neurocognitive disorders.